Scholarlink

Purpose of the review <p>&#xa0;In the last ten years, many clinical trials evaluating the efficacy of targeted therapies in polymyalgia rheumatica (PMR) have been published. Knowledge in this field is evolving very rapidly and a review of the current evidence available will help physician to follow these many innovations.&#xa0;</p> Recent findings <p>The interleulin-6 receptor inhibitors – tocilizumab and sarilumab – have been evaluated in several randomized controlled trials. The results are consistent and demonstrate an efficacy of these drugs in early PMR and in relapsing or in glucocorticoid-dependent PMR. Among the therapies targeting lymphocytes, rituximab was efficient in decreasing the PMR-AS and preventing the use of long-term glucocorticoids. On the other hand, abatacept was not proven efficient in early PMR. The other promising drugs are baricitinib and secukinumab. Baricitinib was superior to placebo in a small randomized controlled trial. Secukinumab was Mainly studied in giant cell arteritis, but an international phase 3 trial is ongoing in PMR.</p> Summary <p>In the last national recommendations for the management of PMR published (in France and in Norway), the use of targeted therapies (tocilizumab and sarilumab) has been incorporated in early disease or in relapsing disease.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Will Targeted Therapies Shape the Future of Polymyalgia Rheumatica Treatment?

  • 期刊论文

  • 发表日期：

    2025年11月14日

查看全文
  • Pablo Leuret-Valles,
  • Guillermo Carvajal Alegria

摘要

Purpose of the review

 In the last ten years, many clinical trials evaluating the efficacy of targeted therapies in polymyalgia rheumatica (PMR) have been published. Knowledge in this field is evolving very rapidly and a review of the current evidence available will help physician to follow these many innovations. 

Recent findings

The interleulin-6 receptor inhibitors – tocilizumab and sarilumab – have been evaluated in several randomized controlled trials. The results are consistent and demonstrate an efficacy of these drugs in early PMR and in relapsing or in glucocorticoid-dependent PMR. Among the therapies targeting lymphocytes, rituximab was efficient in decreasing the PMR-AS and preventing the use of long-term glucocorticoids. On the other hand, abatacept was not proven efficient in early PMR. The other promising drugs are baricitinib and secukinumab. Baricitinib was superior to placebo in a small randomized controlled trial. Secukinumab was Mainly studied in giant cell arteritis, but an international phase 3 trial is ongoing in PMR.

Summary

In the last national recommendations for the management of PMR published (in France and in Norway), the use of targeted therapies (tocilizumab and sarilumab) has been incorporated in early disease or in relapsing disease.